Edgewood Management
ALXN

Edgewood Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Edgewood Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5,094
Closed -$609K – 82
2017
Q4 		$609K Hold
5,094
– – ﹤0.01% 57
2017
Q3 		$715K Sell
5,094
-84
-2% -$11.4K ﹤0.01% 51
2017
Q2 		$630K Hold
5,178
– – ﹤0.01% 54
2017
Q1 		$628K Sell
5,178
-117
-2% -$15.1K ﹤0.01% 51
2016
Q4 		$648K Sell
5,295
-4,660
-47% -$570K ﹤0.01% 51
2016
Q3 		$1.22M Buy
+9,955
New +$1.28M 0.01% 44

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Edgewood Management's ALXN Position: Q1 2018 in Review

Edgewood Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 5,094 shares — an estimated $609K sold.

Edgewood Management first reported a position in ALXN in Q3 2016 and held it in 6 quarters. The position peaked at $1.22M in Q3 2016. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • Edgewood Management reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Edgewood Management sold 5,094 Alexion Pharmaceuticals shares in Q1 2018, an estimated $609K.
  • Edgewood Management first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 6 quarters.
  • Edgewood Management's Alexion Pharmaceuticals position peaked at $1.22M in Q3 2016.
  • 596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Edgewood Management's 13F filing for Q1 2018, filed 11 May 2018.